Stockscreener 앱 받기
3.00
1.32%
-0.04
시간 외 거래:
3.00
전일 마감가:
$3.04
열려 있는:
$3.09
하루 거래량:
15.27M
Relative Volume:
0.77
시가총액:
$1.59B
수익:
$66.41M
순이익/손실:
$-559.78M
주가수익비율:
-2.4954
EPS:
-1.2022
순현금흐름:
$-328.09M
1주 성능:
+1.35%
1개월 성능:
-18.26%
6개월 성능:
-28.40%
1년 성능:
-49.58%
1일 변동 폭
$2.95
$3.105
1주일 범위
$2.86
$3.13
52주 변동 폭
$2.77
$7.18
리커젼 파마 Stock (RXRX) Company Profile
명칭
Recursion Pharmaceuticals Inc
전화
(385) 269-0203
주소
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.00 | 1.60B | 66.41M | -559.78M | -328.09M | -1.2022 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
리커젼 파마 Stock (RXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-07-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-22 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 개시 | Needham | Buy |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-04 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 개시 | Berenberg | Buy |
| 2021-05-11 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Goldman | Neutral |
| 2021-05-11 | 개시 | JP Morgan | Neutral |
| 2021-05-11 | 개시 | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 개시 | SVB Leerink | Outperform |
모두보기
리커젼 파마 주식(RXRX)의 최신 뉴스
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance Singapore
Recursion Pharmaceuticals, Inc. Class A Revenue Breakdown – BIVA:RXRX - TradingView
RXRX (RXRX) insider details 50,000-share planned sale and recent stock trades - Stock Titan
RXRX|Recursion Pharmaceuticals Inc|Price:3.030| - TradingKey
Recursion Pharmaceuticals Inc (RXRX) Cash Flow - TradingKey
RXRX|Recursion Pharmaceuticals Inc|Price:3.000|Chg%:-0.010 - TradingKey
AI Stocks: Why Tempus AI (NASDAQ:TEM), Recursion Pharmaceuticals (NASDAQ:RXRX) and Schrodinger (NASDAQ:SDGR) Are in Focus - Kalkine Media
TradingKey - TradingKey
Recursion Pharmaceuticals Stock (RXRX) Opinions on Trading Ranges and Biotech Prospects - Quiver Quantitative
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Recursion Pharmaceuticals Inc (RXRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Recursion Pharmaceuticals, Inc (RXRX) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Recursion Pharmaceuticals Inc (RXRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Recursion Pharmaceuticals Inc (RXRX) Institutional Confidence - TradingKey
RXRX|Recursion Pharmaceuticals Inc|Price:3.019|Chg%:+0.059 - TradingKey
Recursion Pharmaceuticals, Inc. (RXRX) Options Chain - Yahoo! Finance Canada
Recursion Pharmaceuticals Inc (RXRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Recursion Pharmaceuticals (RXRX) Proxy filing Summary - Quartr
Recursion Pharmaceuticals (RXRX) Guggenheim Securities 2nd Annual Healthcare Innovation Conference summary - Quartr
Recursion Pharmaceuticals Inc (RXRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
RXRX insider to sell 100,000 Class A shares (NASDAQ: RXRX) after prior large trades - Stock Titan
Recursion Pharmaceuticals Stock Short Interest Falls to 34.41% - Quiver Quantitative
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Exploring a 150% Upside Potential in Biotechnology - DirectorsTalk Interviews
RXRX: Recursion Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
RXRX (RXRX) insider files Form 144 to sell 100,000 Class A shares - Stock Titan
Form 144 RECURSION PHARMACEUTICALS For: 17 July By Investing.com - Investing.com Canada
Form 144 RECURSION PHARMACEUTICALS For: 16 July By Investing.com - Investing.com Nigeria
RXRX Stock Slips Onto Watchlists After Insider Form 144 - timothysykes.com
RXRX Stock Under Pressure As Insider Signals Share Sale - StocksToTrade
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today - Yahoo Finance
Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy? - The Globe and Mail
Form 144 RECURSION PHARMACEUTICALS For: 13 July By Investing.com - Investing.com Australia
Price to sales forward of Recursion Pharmaceuticals, Inc. – NASDAQ:RXRX - TradingView
Price to book forward of Recursion Pharmaceuticals, Inc. – NASDAQ:RXRX - TradingView
Enterprise value to revenue forward of Recursion Pharmaceuticals, Inc. – NASDAQ:RXRX - TradingView
Price to earnings forward of Recursion Pharmaceuticals, Inc. – NASDAQ:RXRX - TradingView
Recursion Pharmaceuticals (RXRX) Highlights Clinical Progress, Is The Stock Fully Priced? - Sahm
2 Beaten-Down Stocks That Still Aren't Worth Buying - The Motley Fool
2 Beaten-Down Stocks That Still Aren't Worth Buying - The Motley Fool
Recursion Pharmaceuticals Stock (RXRX) Opinions on Biotech AI Prospects - Moomoo
Form 144 RECURSION PHARMACEUTICALS For: 10 July By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals (RXRX) Goldman Sachs 46th Annual Global Healthcare Conference 2025 summary - Quartr
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake - Moomoo
Insider Sell: Blake Borgeson Sells 40,000 Shares of Recursion Ph - GuruFocus
Form 4 Recursion Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals director Borgeson sells $158,500 stock By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals director Borgeson sells $158,500 stock - Investing.com
리커젼 파마 (RXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.44%
0.02%
자본화:
|
볼륨(24시간):